At present, great efforts have been made to discover inhibitors of PI3K/Akt pathway for the treatment of cancer and a number of these inhibitors have been approved or are evaluated in clinical trials, such as Idelalisib, BEZ-235, ZSTK474, PI-103, XL-765, BYL-719, and PX-866 (Cohen, 2014; Kumar et al., 2015; Massacesi et al., 2016; Zhao et al., 2017). The gene discussed is AKT1; the disease is cancer.